`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`
`OXFORD NANOPORE TECHNOLOGIES, INC.
`Petitioner
`
`v.
`
`PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
`Patent Owner
`
`____________
`
`
`Case No. IPR2018-01792
`U.S. Patent No. 9,738,929
`
`____________
`
`PETITIONER’S REPLY TO PATENT OWNER’S PRELIMINARY
`RESPONSE PURSUANT TO 37 C.F.R. § 42.108(c)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I. INTRODUCTION
`
`Oxford Nanopore Technologies, Inc. (“Petitioner”) filed a Petition, Paper 1
`
`(“Petition”), to institute inter partes review (“IPR”) of claims 1-17 of U.S. Patent
`
`No. 9,738,929 (“the ’929 Patent”). Pacific Biosciences of California, Inc. (“Patent
`
`Owner”) filed a Preliminary Response, Paper 6 (“Prelim. Resp.”), contending, in
`
`part, that the Board should deny the Petition under 35 U.S.C. § 314(a). Prelim.
`
`Resp., 5. The Board authorized Petitioner to file a Reply to the Patent Owner’s
`
`Preliminary Response to address Patent Owner’s arguments regarding the timing
`
`of the Petition in relation to a concurrent litigation. Paper 7 (January 30, 2019).
`
`II. RELATED PROCEEDINGS
`
`The ’929 Patent is subject to a pending lawsuit entitled Pacific Biosciences
`
`of California, Inc., v. Oxford Nanopore Technologies, Inc., which was consolidated
`
`into actions 1:17-cv-00275-LPS, 1:17-cv-01353-LPS (D. Del.) (“the Delaware
`
`Proceeding”), in which Petitioner is a defendant.
`
`III. ARGUMENT
`
`Patent Owner contends that “the Board should exercise its discretion not to
`
`institute trial here, as it would be a waste of both the Board’s and the Parties’
`
`resources and fundamentally at odds with Congress’s intent for IPR proceedings.”
`
`Prelim. Resp., 10. The Board has identified the following seven factors to be
`
`considered in exercising discretion to institute under 35 U.S.C. § 314(a):
`
`
`
`- 1 -
`
`
`
`
`
`
`
`1. whether the same petitioner previously filed a petition directed to
`the same claims of the same patent; 2. whether at the time of filing of
`the first petition the petitioner knew of the prior art asserted in the
`second petition or should have known of it; 3. whether at the time of
`filing of the second petition the petitioner already received the patent
`owner’s preliminary response to the first petition or received the
`Board’s decision on whether to institute review in the first petition; 4.
`the length of time that elapsed between the time the petitioner learned
`of the prior art asserted in the second petition and the filing of the
`second petition; 5. whether
`the petitioner provides adequate
`explanation for the time elapsed between the filings of multiple
`petitions directed to the same claims of the same patent; 6. the finite
`resources of the Board; and 7. the requirement . . . to issue a final
`determination not later than 1 year after . . . institution of review.
`
`General Plastic Industrial Co., Ltd. v. Canon Kabushiki Kaisha, Case IPR2016-
`
`01357, Paper 19 (PTAB Sept. 6, 2017), 16. The Board’s intent in formulating the
`
`General Plastic factors was “to take undue inequities and prejudices to Patent
`
`Owner into account.” Id., 17. Applying the General Plastic factors to the facts at
`
`hand, Petitioner has gained no unfair advantage, Patent Owner has not been
`
`prejudiced, and the Board’s resources will not be wasted by institution of this IPR.
`
`As Patent Owner concedes, factor one favors institution as Petitioner has not
`
`previously filed an IPR petition challenging the ’929 patent. Prelim. Resp., 11-12.
`
`Factors two through five address situations where a delay in filing grants
`
`
`
`- 2 -
`
`
`
`
`
`
`
`Petitioner an unfair advantage. Expedia, Inc. v. International Business Machines
`
`Corporation, Case IPR2018-01354, Paper 8 (PTAB January 15, 2019), 33
`
`(“[Factors two through five ask] whether Petitioner unfairly waited to raise prior
`
`art in a petition until after allegations were presented in another case and ruled
`
`upon, thereby giving a Petitioner a road map on how to improve its case.”). Patent
`
`Owner does not allege Petitioner gained any unfair advantage from the Delaware
`
`Proceeding. Instead, Patent Owner’s sole argument concerning “unfair advantage”
`
`is predicated on Petitioner having the benefit of the Patent Owner’s Preliminary
`
`Response and the Board’s Denial of Institution in an IPR on a different patent,
`
`Oxford Nanopore Tech., Inc. v. Pacific Biosciences of California, Inc., Case
`
`IPR2018-00789. Prelim. Resp., 7 and 12. Patent Owner’s conclusory position,
`
`however, is not supported by the facts.
`
`Patent Owner has argued that the patent at issue in IPR2018-00789, U.S.
`
`Patent No. 9,546,400 (“the ’400 Patent”), is directed to the recognition “that
`
`multiple bases within a nanopore typically contribute to the signal, [and that] the
`
`inventors developed an approach specific to nanopore-based DNA sequencing in
`
`which calibration information based on all 4N sequence combinations . . . is used to
`
`sequence the nanopore signal.” Oxford Nanopore, Case IPR2018-00789, Paper 7
`
`(July 5, 2018), 14. In contrast, Patent Owner argues that the ’929 Patent is directed
`
`to “the ability to determine a consensus sequence from just the sense and anti-sense
`
`
`
`- 3 -
`
`
`
`
`
`
`
`strands of a single-molecule with nanopore sequencing.” Prelim. Resp., 34, n.2.
`
`Given these differences in subject matter, Petitioner could not, and did not, gain
`
`any unfair advantage by having access to the Patent Owner’s Preliminary Response
`
`or the Institution Decision in IPR2018-00789 prior to filing the instant Petition.
`
`Moreover, neither the Patent Owner’s Preliminary Response nor the Institution
`
`Decision in IPR2018-00789 analyzed or discussed the disclosure of the single
`
`reference in common between the two proceedings, U.S. Patent Publication No.
`
`2006/0063171, beyond a passing reference in the “Background” of the Patent
`
`Owner Preliminary Response. See IPR2018-00789, Paper 7, 12; IPR2018-00789,
`
`Paper 8 (Sept. 25, 2018). Because no unfair “road map” could have been obtained
`
`based on the proceedings of IPR2018-00789, factors two through five also fall
`
`decidedly in favor of institution of the instant Petition.
`
`Patent Owner alleges that the roughly two-month period between filing of
`
`invalidity contentions in the Delaware Proceeding and the filing of the Petition
`
`allowed Petitioner to obtain an unspecified “unfair advantage” under factor 4 and
`
`leads factor 5 to weigh against institution or be neutral. Prelim. Resp., 12.
`
`Roughly two months to prepare and file an IPR petition and supporting expert
`
`declaration hardly constitutes undue delay, particularly in the absence, as here, of
`
`any factual evidence supporting the alleged unfair advantage.
`
`The Patent Owner contends that factors six and seven weigh in favor of
`
`
`
`- 4 -
`
`
`
`
`
`
`
`denial because “the district court litigation is at an advanced stage, and trial will
`
`conclude before a final decision will issue in this proceeding.” Id., 7. Patent
`
`Owner’s protestation that it would be a waste of resources to institute the instant
`
`IPR ignores the fact that validity in the District Court litigation and the instant IPR
`
`would be governed by entirely distinct standards, thus a conclusion of validity in
`
`District Court would not preclude a finding of unpatentability in the IPR, even on
`
`identical records. Novartis AG v. Noven Pharm. Inc., 853 F.3d 1289, 1294 (Fed.
`
`Cir. 2017). Moreover, not only would appeals in both proceedings almost certainly
`
`be co-pending, if not consolidated, as the current trial date, March 9, 2020, is
`
`roughly one month earlier than the April 11, 2020 deadline for a Final
`
`Determination, but the issuance of a Final Determination affirmed in a later-filed
`
`IPR appeal could be used by the Federal Circuit to dismiss as moot an earlier-filed
`
`District Court appeal. Dragon Intellectual Property, LLC v. Apple Inc., 700 Fed.
`
`Appx. 1005 (Fed. Cir. 2017). Thus, factors six and seven also favor institution.
`
`IV. CONCLUSION
`
`For the foregoing reasons, the Board should decline to invoke its discretion
`
`under 35 U.S.C. §§ 314(a) and 324(a) to deny institution of the Petition.
`
`
`
`
`
`
`
`Respectfully submitted,
`
`BAKER BOTTS L.L.P.
`
`Date: February 6, 2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Steven P. Lendaris/
`Steven P. Lendaris (Reg. No. 53,202)
`
`
`
`
`
`- 5 -
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`In accordance with 37 C.F.R. §§ 42.6(e) and 42.105, the undersigned
`
`certifies that on February 6, 2019, a complete and entire copy of the foregoing was
`
`provided by electronic service to counsel retained by Patent Owner in the Related
`
`Matters identified herein:
`
`PacBio.Oxford.Delaware@weil.com
`
`
`
`Respectfully submitted,
`
`BAKER BOTTS L.L.P.
`
`
`
`
`/Steven P. Lendaris/
`Steven P. Lendaris (Reg. No. 53,202)
`
`Date: February 6, 2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`